Nuvelo to merge with Arca
This article was originally published in Scrip
Executive Summary
Nuvelo and Arca Biopharma are to merge, a move that is likely to improve the fortunes of the larger California-based company. It has struggled since its lead product, alfimeprase, was discontinued in March after disappointing results in the Phase II SONOMA-3 trial in catheter occlusion.